Nivolumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma
Conditions
Lymphoma
Trial Timeline
Oct 21, 2016 → Nov 24, 2020
NCT ID
NCT02857426About Nivolumab
Nivolumab is a phase 2 stage product being developed by Ono Pharmaceutical for Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02857426. Target conditions include Lymphoma.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03987815 | Phase 2 | UNKNOWN |
| NCT03383458 | Phase 3 | Active |
| NCT03090737 | Phase 2 | Completed |
| NCT02857426 | Phase 2 | Completed |
| NCT02743494 | Phase 3 | Completed |
| NCT02632409 | Phase 3 | Active |
| NCT02387996 | Phase 2 | Completed |
Competing Products
20 competing products in Lymphoma